NWBO - Northwest Biotherapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.204
+0.002 (+0.99%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.202
Open0.200
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.200 - 0.205
52 Week Range0.160 - 0.400
Volume716,508
Avg. Volume1,922,166
Market Cap91.182M
Beta2.73
PE Ratio (TTM)N/A
EPS (TTM)-0.320
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Trade prices are not sourced from all markets
  • PR Newswire3 months ago

    NW Bio To Discuss Interim Phase 3 Trial Data In Industry Theater Session During ASCO

    BETHESDA, Maryland, June 1, 2018 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that on Sunday, June 3, at 4:15 p.m. Central Time in the Industry Expert Theater in the Exhibit Hall at the ASCO Conference in the McCormick Place Convention Center in Chicago, Illinois, Dr. Marnix L. Bosch, Chief Technical Officer of NW Bio, will discuss the interim data that was published on May 29 from the Company's Phase 3 trial of DCVax®-L for newly diagnosed Glioblastoma brain cancer. Arrangements are being made for Dr. Bosch's presentation to be webcast.  Details will be posted on the Company's website (www.nwbio.com) under the heading "Most Recent Presentations" when the arrangements are completed.  It is anticipated that the webcast will be available for review after the presentation on the Company's website.  This presentation is not an official presentation of the 2018 ASCO Annual Meeting.  It is not sponsored, endorsed, or accredited by ASCO or the Conquer Cancer Foundation.

  • PR Newswire3 months ago

    NW Bio To Discuss Interim Phase 3 Trial Data In Industry Theater Session During ASCO

    BETHESDA, Md., May 31, 2018 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that on Sunday, June 3, at 4:15 p.m. Central Time in the Industry Expert Theater in the Exhibit Hall at the ASCO Conference in the McCormick Place Convention Center in Chicago, Illinois, Dr. Marnix L. Bosch, Chief Technical Officer of NW Bio, will discuss the interim data that was published on May 29 from the Company's Phase 3 trial of DCVax®-L for newly diagnosed Glioblastoma brain cancer. Arrangements are being made for Dr. Bosch's presentation to be webcast.  Details will be posted on the Company's website (www.nwbio.com) under the heading "Most Recent Presentations" when the arrangements are completed.  It is anticipated that the webcast will be available for review after the presentation on the Company's website.  This presentation is not an official presentation of the 2018 ASCO Annual Meeting.  It is not sponsored, endorsed, or accredited by ASCO or the Conquer Cancer Foundation.

  • PR Newswire3 months ago

    NWBio Announces Scientific Publication of Interim Survival Data From Phase 3 Trial of DCVax®-L for Glioblastoma Brain Cancer

    BETHESDA, Md., May 29, 2018 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today the publication of interim blinded survival data from its Phase 3 clinical trial of DCVax®-L for newly diagnosed Glioblastoma brain cancer.  The data were collected by the independent contract research organization managing the trial, tabulated by an independent statistical firm and published with 69 co-authors in the peer reviewed Journal of Translational Medicine (JTM). The trial is ongoing while the data continue to mature, and the Company, the investigators and patients all remain blinded. The interim data set forth in the JTM publication are blinded aggregate data which include patients from both arms of the trial combined: the arm with 2/3 of the patients, who received standard of care plus DCVax-L, and the arm with 1/3 of the patients, who received standard of care plus a placebo.  When the patients experienced tumor recurrence, all patients from both arms were allowed to cross over and start receiving DCVax-L, but without being unblinded as to what they had received before tumor recurrence.  The patient population enrolled in the trial is similar to that in other recent trials, and more than 75% of the patients were over 50 years old (a factor associated with less favorable outcomes).

  • Associated Press3 months ago

    Northwest Biotherapeutics: 1Q Earnings Snapshot

    The Bethesda, Maryland-based company said it had a loss of 9 cents per share. Losses, adjusted for one-time gains and costs, came to 6 cents per share. The cancer drug developer posted revenue of $132,000 ...

  • NW Bio Releases Vote Tallies From Special Shareholder Meeting
    PR Newswire4 months ago

    NW Bio Releases Vote Tallies From Special Shareholder Meeting

    BETHESDA, Md., May 1, 2018 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today released the vote tallies for the three proposals on the ballot at its Special Meeting of Shareholders held last Friday afternoon in Washington, DC. Proposal 1 was to raise the ceiling on the total number of authorized shares of common stock of the Company from 450 million to 1.2 billion.  For this Proposal, only the common shares could vote.  This Proposal was approved, with Yes votes from 87% of the votes cast (245,267,573), with 4% voting against (11,699,346), and 9% abstaining (25,836,335 votes).  30% did not vote (131,861,943). Proposal 2 was to raise the ceiling on the total number of authorized shares of preferred stock of the Company from 40 million to 100 million.  For this Proposal, both the preferred stock and the common stock could vote.  This Proposal was approved with Yes votes from 86% of the votes cast (327,025,901), with 7% voting against (27,266,121), and 7% abstaining (25,796,199).

  • PR Newswire4 months ago

    NW Bio Announces Additional Funding

    On April 26, 2018, the Company and Ms. Powers entered into a note and loan agreement for an additional loan of $1.0 million by Ms. Powers to the Company on the same terms as her prior funding, as previously reported in March.  The Note is convertible into Series B Preferred Stock at $2.30 per share (with each share of Series B Preferred Stock convertible into ten shares of Common Stock at $0.23 per share), and Class D-2 Warrants exercisable for an equal number of shares of Common Stock at $0.30 per share, with warrants on half of the Note repayment amount due and issuable when the loan was provided, and warrants on half of the Note repayment amount due on a proportional basis in the event of conversion of some or all of the Note.

  • ACCESSWIRE6 months ago

    Independent Research on Trending Growth Companies: Northwest Biotherapeutics and Sanuwave Health

    NEW YORK, NY / ACCESSWIRE / February 26, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of Northwest Biotherapeutics, Inc. (OTCQB: NWBO) and Sanuwave Health ...

  • NW Bio Congratulates Cognate BioServices On Its Management Buyout
    PR Newswire6 months ago

    NW Bio Congratulates Cognate BioServices On Its Management Buyout

    BETHESDA, Md., Feb. 20, 2018 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, congratulated Cognate BioServices, the contract manufacturer of NWBio's DCVax® products, on the Management Buyout of Cognate supported by global institutional investors, which Cognate announced today. Following this transaction, neither Linda Powers nor any Toucan Capital related entities have any ownership interest in Cognate or any role on Cognate's Board. More information can be found in a Cognate press release at https://www.businesswire.com/news/home/20180220006077/en.

  • PR Newswire8 months ago

    NW Bio Announces Regulation D Offering for Accredited Investors

    BETHESDA, Md., Dec. 19, 2017 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) -- (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it is commencing a general solicitation Regulation D offering  to accredited investors.  The Offering will remain open for execution of subscription agreements until 5:30 pm EST on Wednesday, December 27, 2017, and the closing is expected to take place on Friday, December 29, 2017.

  • NW Bio Announces Completion of $12 Million Financing
    PR Newswire8 months ago

    NW Bio Announces Completion of $12 Million Financing

    BETHESDA, Md., Dec. 4, 2017 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) (NWBio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it has completed a $12 million financing to fund operations.  The majority of the financing is being provided by new investors. The financing is in the form of Series A Convertible Preferred Stock and Warrants.  The Preferred Stock will be convertible into common stock, but only when common stock is available or after 6 months following issuance.  The Warrants will be exercisable for common stock, but only when common stock is available.  The shares are registered, but are subject to restrictions under which they may not be conveyed or traded until a shareholder vote takes place, pursuant to which the number of authorized shares is increased.  The shares are also subject to a voting agreement, under which the investors have agreed to vote in support of such increase in authorized shares.

  • NW Bio Reports Favorable Results and Progress In Resolving Lawsuits
    PR Newswire10 months ago

    NW Bio Reports Favorable Results and Progress In Resolving Lawsuits

    BETHESDA, Md., Oct. 30, 2017 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, is pleased to report meaningful progress in resolving four lawsuits that were brought against it as reported in the Company's periodic filings. Every claim was dismissed.  On April 12, 2017, the lead plaintiffs submitted a letter to the court advising it that they were not going to file an amended complaint, and the deadline for filing an appeal has now expired.  This action is over.

  • NW Bio Reports Favorable Results and Progress In Resolving Lawsuits
    PR Newswire10 months ago

    NW Bio Reports Favorable Results and Progress In Resolving Lawsuits

    BETHESDA, Md., Oct. 25, 2017 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, is pleased to report meaningful progress in resolving four lawsuits that were brought against it as reported in the Company's periodic filings. Every claim was dismissed.  On April 12, 2017, the lead plaintiffs submitted a letter to the court advising it that they were not going to file an amended complaint, and the deadline for filing an appeal has now expired.  This action is over.

  • NW BIO Announces Registered Direct Offering Of $1.75 Million
    PR Newswire11 months ago

    NW BIO Announces Registered Direct Offering Of $1.75 Million

    BETHESDA, Md., Sept. 20, 2017 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into definitive agreements with institutional investors for a registered direct offering with gross proceeds of $1.75 million. In the transaction, the Company will sell approximately 8.75 million shares of common stock at a purchase price of $0.20 per share.  Additionally, the investors will receive five year warrants to purchase up to approximately 4.375 million shares of common stock with an exercise price of $0.22 per share.

  • Capital Cube11 months ago

    ETFs with exposure to Northwest Biotherapeutics, Inc. : September 6, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Northwest Biotherapeutics, Inc. Here are 5 ETFs with the largest exposure to NWBO-US. Comparing the performance and risk of Northwest Biotherapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • DCVax® Clinical Program Updates Presented By Dr. Marnix Bosch At Boston Scientific Conference
    PR Newswirelast year

    DCVax® Clinical Program Updates Presented By Dr. Marnix Bosch At Boston Scientific Conference

    DCVax®-L Phase III GBM Trial & DCVax-Direct Phase I/II Updates; Overview Of A Broader Range Of DC Vax Public Data BETHESDA, Md. , Sept. 1, 2017 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (NW ...